Pharmacokinetic and Pharmacodynamic Properties of Eptifibatide in Healthy Subjects Receiving Unfractionated Heparin or the Low-Molecular-Weight Heparin Enoxaparin

Clinical Therapeutics

Volumn 25, Issue 10, 2003, Pages 2564-2574

  Gretler, Daniel D ^a  

^a MILLENNIUM PHARMACEUTICALS INC   (United States)

Author keywords

Glycoprotein IIb IIIa inhibitors; Heparin; Pharmacodynamics; Pharmacokinetics

Indexed keywords

ENOXAPARIN; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG TOLERABILITY; FEMALE; HEART MUSCLE ISCHEMIA; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; ST SEGMENT ELEVATION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTOPENIA; TRANSLUMINAL CORONARY ANGIOPLASTY;

EID: 0242593750     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(03)80317-X     Document Type: Article

References (15)

1. Platelet Glycoprotein IIb/IIIa in Unstable Angina Receptor Suppression Using Integrilin Therapy (PURSUIT) Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med. 1998;339: 436-443.
2. Fintel DJ, Ledley GS. Management of patients with non-ST-segment elevation acute coronary syndromes: Insights from the PURSUIT trial. Clin Cardiol. 2000;23(Suppl 5): V1-V12.
3. Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin Therapy (ESPRIT) Trial Investigators. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): A randomised, placebo-controlled trial [published correction appears in Lancet. 2001;357:1370]. Lancet. 2000;356:2037-2044.
4. O'Shea JC, Hafley GE, Greenberg S, et al, for the Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin Therapy (ESPRIT) Trial Investigators. Platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention: The ESPRIT trial: A randomized controlled trial. JAMA. 2001;285:2468-2473.
5. O'Shea JC, Buller CE, Cantor WJ, et al, for the Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin Therapy (ESPRIT) Trial Investigators. Long-term efficacy of platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention. JAMA. 2002;287:618-621.
6. Peterson JG, Topol EJ, Roe MT, et al, for the Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) Trial Investigators. Prognostic importance of concomitant heparin with eptifibatide in acute coronary syndromes. Am J Cardiol. 2001;87:532-536.
7. Lefkovits J, Plow EF, Topol EJ. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N Engl J Med. 1995;332:1553-1559.
8. Hirsh J, Anand SS, Halperin JL, Fuster V, for the American Heart Association. Guide to anticoagulant therapy: Heparin: A statement for healthcare professionals from the American Heart Association. Circulation. 2001;103:2994-3018.
9. Cohen M, Demers C, Gurfinkel EP, et al, for the Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. N Engl J Med. 1997;337:447-452.
10. Antman EM, McCabe CH, Gurfinkel EP, et al. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial. Circulation. 1999;100:1593-1601.
11. Goodman SG, Fitchett D, Armstrong PW, et al, for the Integrilin and Enoxaparin Randomized Assessment of Acute Coronary Syndrome Treatment (INTERACT) Trial Investigators. Randomized evaluation of the safety and efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide. Circulation. 2003;107:238-244.
12. 2+ on GP IIb-IIIa interactions with integrilin: Enhanced GP IIb-IIIa binding and inhibition of platelet aggregation by reductions in the concentration of ionized calcium in plasma anticoagulated with citrate. Circulation. 1997;96:1488-1494.
13. Scarborough RM, Rose JW, Naughton MA, et al. Characterization of the integrin specificities of disintegrins isolated from American pit viper venoms. J Biol Chem. 1993; 268:1058-1065.
14. Ferguson JJ, Antman EA, Bates ER, et al, for the NICE 3 Investigators. The use of enoxaparin and IIb/IIIa antagonists in acute coronary syndromes, including PCI: Final results of the NICE 3 study. J Am Coll Cardiol. 2001;37(Suppl A):365A. Abstract 1253-97.
15. Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients with Unstable Angina). American College of Cardiology and the American Heart Association. J Am Coll Cardiol. 2002;40:366-374. Available at: http://www.acc.org/ clinical/guidelines/unstable/ unstable.pdf.